AstraZeneca still waiting for FDA decision to resume U.S. trial
The U.S. trial of AstraZeneca's COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the United States have resumed. U.S. Health and Human Services Secretary Alex Azar said on Wednesday the continued suspension showed the FDA took vaccine safety seriously.
- Country:
- United Kingdom
AstraZeneca is still waiting for the go-ahead from the U.S. drug regulator to restart the clinical trial of its potential COVID-19 vaccine in the United States, Chief Executive Pascal Soriot said on Thursday.
"We are the sponsor of the U.S. study. We then provided all this information to the FDA (U.S. Federal Drug Administration) and we are waiting to hear their decision," Soriot told a virtual World Economic Forum discussion. The U.S. trial of AstraZeneca's COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the United States have resumed.
U.S. Health and Human Services Secretary Alex Azar said on Wednesday the continued suspension showed the FDA took vaccine safety seriously. A document posted online by Oxford university last week stated the illness in a British participant that triggered the pause on Sept. 6 may not have been associated with the vaccine.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
UN report: Many countries are bouncing back from COVID pandemic but the poorest are not
Health News Roundup: US FDA staff raise concerns over data from J&J, Bristol's CAR-T therapies; Bird flu strain raises alarm as virus kills South American wildlife and more
US FDA expands use of Bristol Myers' cancer therapy
Health News Roundup: US FDA approves expanded use of Mirum's liver disease drug; US' Harris visits Minnesota abortion clinic in historic first and more
Health News Roundup: US FDA expands use of Bristol Myers' cancer therapy; Reckitt unit hit with $60 million verdict in Enfamil baby formula case in Illinois and more